Shiga toxin receptor glycolipid binding. Pathology and utility.

[1]  C. MacKenzie,et al.  A Mutational Analysis of the Globotriaosylceramide-binding Sites of Verotoxin VT1* , 2002, The Journal of Biological Chemistry.

[2]  C. Lingwood,et al.  Verotoxin targets lymphoma infiltrates of patients with post-transplant lymphoproliferative disease. , 2000, Leukemia research.

[3]  P. Ricciardi-Castagnoli,et al.  The B Subunit of Shiga Toxin Fused to a Tumor Antigen Elicits CTL and Targets Dendritic Cells to Allow MHC Class I-Restricted Presentation of Peptides Derived from Exogenous Antigens1 , 2000, The Journal of Immunology.

[4]  R. Cummings,et al.  Cloning of Gb3 Synthase, the Key Enzyme in Globo-series Glycosphingolipid Synthesis, Predicts a Family of α1,4-Glycosyltransferases Conserved in Plants, Insects, and Mammals* , 2000, The Journal of Biological Chemistry.

[5]  R. Steffensen,et al.  Cloning and Expression of the Histo-blood Group PkUDP-galactose:Galβ1–4Glcβ1-Cer α1,4-Galactosyltransferase , 2000, The Journal of Biological Chemistry.

[6]  C. Lingwood,et al.  Enterohemorrhagic Escherichia coliInduces Apoptosis Which Augments Bacterial Binding and Phosphatidylethanolamine Exposure on the Plasma Membrane Outer Leaflet , 2000, Infection and Immunity.

[7]  Kazuro Furukawa,et al.  Molecular Cloning of Globotriaosylceramide/CD77 Synthase, a Glycosyltransferase That Initiates the Synthesis of Globo Series Glycosphingolipids* , 2000, The Journal of Biological Chemistry.

[8]  B. Zanke,et al.  Escherichia coli Shiga toxins induce apoptosis in epithelial cells that is regulated by the Bcl-2 family. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[9]  R. Read,et al.  A mutant Shiga-like toxin IIe bound to its receptor Gb(3): structure of a group II Shiga-like toxin with altered binding specificity. , 2000, Structure.

[10]  R. Read,et al.  Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands , 2000, Nature.

[11]  G. Magnusson,et al.  Synthesis of some aglycon analogs of globotriosylceramide. , 1999, Carbohydrate research.

[12]  C. Lingwood,et al.  Globotriaosyl ceramide modulates interferon-α-induced growth inhibition and CD19 expression in Burkitt's lymphoma cells , 1999, Glycoconjugate Journal.

[13]  D. Acheson,et al.  Shiga Toxins 1 and 2 Translocate Differently across Polarized Intestinal Epithelial Cells , 1999, Infection and Immunity.

[14]  N. Kushnir,et al.  Dendritic cells, B cells and the regulation of antibody synthesis , 1999, Immunological reviews.

[15]  D. Philpott,et al.  Phosphatidylethanolamine recognition promotes enteropathogenic E. coli and enterohemorrhagic E. coli host cell attachment. , 1999, Microbial pathogenesis.

[16]  J. Gariépy,et al.  Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation. , 1999, Blood.

[17]  C. Lingwood.  Verotoxin/Globotriaosyl Ceramide Recognition: Angiopathy, Angiogenesis and Antineoplasia , 1999, Bioscience reports.

[18]  R. Read,et al.  The identification of three biologically relevant globotriaosyl ceramide receptor binding sites on the Verotoxin 1 B subunit , 1999, Molecular microbiology.

[19]  C. Lingwood,et al.  Adamantyl globotriaosyl ceramide: a monovalent soluble mimic which inhibits verotoxin binding to its glycolipid receptor. , 1999, Biochemical and biophysical research communications.

[20]  N. Hooper.  Detergent-insoluble glycosphingolipid/cholesterol-rich membrane domains, lipid rafts and caveolae (review). , 1999, Molecular membrane biology.

[21]  H. O'brodovich,et al.  Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer , 1999, Gene Therapy.

[22]  D. Milford,et al.  A comparison of the effects of verocytotoxin-1 on primary human renal cell cultures. , 1999, Toxicology letters.

[23]  S. Yamasaki,et al.  Induction of cytokines in a human colon epithelial cell line by Shiga toxin 1 (Stx1) and Stx2 but not by non‐toxic mutant Stx1 which lacks N‐glycosidase activity , 1999, FEBS letters.

[24]  J. Rutka,et al.  Verotoxins inhibit the growth of and induce apoptosis in human astrocytoma cells , 1998, Journal of Neuro-Oncology.

[25]  H. Abboud,et al.  Shiga toxin 1 elicits diverse biologic responses in mesangial cells. , 1998, Kidney international.

[26]  T. Koerner,et al.  Shiga Toxin Binds Human Platelets via Globotriaosylceramide (Pk Antigen) and a Novel Platelet Glycosphingolipid , 1998, Infection and Immunity.

[27]  T. Yutsudo,et al.  No Direct Effects of Shiga Toxin 1 and 2 on the Aggregation of Human Platelets In Vitro , 1998, Thrombosis and Haemostasis.

[28]  E. Tartour,et al.  Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B‐fragment of Shiga toxin , 1998, European journal of immunology.

[29]  C. Lingwood,et al.  CD77‐dependent retrograde transport of CD19 to the nuclear membrane: Functional relationship between CD77 and CD19 during germinal center B‐cell apoptosis , 1998, Journal of cellular physiology.

[30]  H. Uchida,et al.  Induction of apoptosis in normal human renal tubular epithelial cells by Escherichia coli Shiga toxins 1 and 2. , 1998, The Journal of infectious diseases.

[31]  H. Uchida,et al.  Verotoxins induce apoptosis in human renal tubular epithelium derived cells. , 1998, Kidney international.

[32]  L. Monnens,et al.  Monocyte Chemoattractant Protein-1 and Interleukin-8 Levels in Urine and Serum of Patents with Hemolytic Uremic Syndrome , 1998, Pediatric Research.

[33]  D. Philpott,et al.  Signal Transduction Pathways Involved in Enterohemorrhagic Escherichia coli-Induced Alterations in T84 Epithelial Permeability , 1998, Infection and Immunity.

[34]  S. Grinstein,et al.  Noninvasive measurement of the pH of the endoplasmic reticulum at rest and during calcium release. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R J Read,et al.  Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. , 1998, Biochemistry.

[36]  R. Read,et al.  Modeling the carbohydrate-binding specificity of pig edema toxin. , 1998, Biochemistry.

[37]  Yang Wang,et al.  Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. , 1998, The Journal of clinical investigation.

[38]  C. Ackerley,et al.  Translocation of verotoxin-1 across T84 monolayers: mechanism of bacterial toxin penetration of epithelium. , 1997, American journal of physiology. Gastrointestinal and liver physiology.

[39]  V. V. van Hinsbergh,et al.  Verocytotoxin inhibits mitogenesis and protein synthesis in purified human glomerular mesangial cells without affecting cell viability: evidence for two distinct mechanisms. , 1997, Journal of the American Society of Nephrology : JASN.

[40]  L. Johannes,et al.  Retrograde Transport of KDEL-bearing B-fragment of Shiga Toxin* , 1997, The Journal of Biological Chemistry.

[41]  E. Ikonen,et al.  Functional rafts in cell membranes , 1997, Nature.

[42]  B. Williams,et al.  Interacting pathways of interferon signaling. , 1997, Seminars in oncology.

[43]  S. Homans,et al.  Solution structure of the carbohydrate-binding B-subunit homopentamer of verotoxin VT-1 from E. coli , 1997, Nature Structural Biology.

[44]  Piet Borst,et al.  MDR1 P-Glycoprotein Is a Lipid Translocase of Broad Specificity, While MDR3 P-Glycoprotein Specifically Translocates Phosphatidylcholine , 1996, Cell.

[45]  S. Grinstein,et al.  Dynamic measurement of the pH of the Golgi complex in living cells using retrograde transport of the verotoxin receptor , 1996, The Journal of cell biology.

[46]  G. van Meer,et al.  Importance of glycolipid synthesis for butyric acid-induced sensitization to shiga toxin and intracellular sorting of toxin in A431 cells. , 1996, Molecular biology of the cell.

[47]  M. Minden,et al.  Shiga-like toxin purges human lymphoma from bone marrow of severe combined immunodeficient mice. , 1996, Blood.

[48]  C. Lingwood.  Aglycone modulation of glycolipid receptor function , 1996, Glycoconjugate Journal.

[49]  D. Acheson,et al.  Translocation of Shiga toxin across polarized intestinal cells in tissue culture , 1996, Infection and immunity.

[50]  J. Gariépy,et al.  Insertion and orientation of a synthetic peptide representing the C-terminus of the A1 domain of Shiga toxin into phospholipid membranes. , 1996, Biochemistry.

[51]  V. V. van Hinsbergh,et al.  Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. , 1996, Blood.

[52]  D. Acheson,et al.  Comparison of the effects of Shiga-like toxin 1 on cytokine- and butyrate-treated human umbilical and saphenous vein endothelial cells. , 1996, The Journal of infectious diseases.

[53]  R. Béliveau,et al.  Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. , 1996, The American journal of physiology.

[54]  V. L. Tesh,et al.  Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines , 1996, Infection and immunity.

[55]  C. Lingwood.  Role of verotoxin receptors in pathogenesis. , 1996, Trends in microbiology.

[56]  B. Rosen,et al.  The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[57]  C. Lingwood,et al.  Shiga toxin-associated hemolytic uremic syndrome: effect of sodium butyrate on sensitivity of human umbilical vein endothelial cells to Shiga toxin , 1995, Infection and immunity.

[58]  D. Milford,et al.  Verocytotoxin-1 induces apoptosis in vero cells. , 1995, The Journal of infection.

[59]  T. Kooistra,et al.  Tumor necrosis factor alpha induces endothelial galactosyl transferase activity and verocytotoxin receptors. Role of specific tumor necrosis factor receptors and protein kinase C. , 1995, Blood.

[60]  A. Molinari,et al.  P‐glycoprotein expression in the Golgi apparatus of multidrug‐resistant cells , 1994, International journal of cancer.

[61]  P. Conrad,et al.  Caveolin moves from caveolae to the Golgi apparatus in response to cholesterol oxidation , 1994, The Journal of cell biology.

[62]  C. Lingwood,et al.  Capping and receptor‐mediated endocytosis of cell‐bound verotoxin (shiga‐like toxin) 1: Chemical identification of an amino acid in the B subunit necessary for efficient receptor glycolipid binding and cellular internalization , 1994, Journal of cellular physiology.

[63]  E. Fish,et al.  Evidence for glycosphingolipid modification of the type 1 IFN receptor. , 1994, Journal of immunology.

[64]  C. Lingwood,et al.  Lipid modulation of glycolipid receptor function , 1994 .

[65]  K. Sandvig,et al.  Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP , 1994, The Journal of cell biology.

[66]  C. Lingwood,et al.  CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis , 1994, The Journal of experimental medicine.

[67]  C. Lingwood,et al.  Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues. , 1994, The Journal of biological chemistry.

[68]  D. Newburg,et al.  Susceptibility to hemolytic-uremic syndrome relates to erythrocyte glycosphingolipid patterns. , 1993, The Journal of infectious diseases.

[69]  I. Pascher,et al.  Steric presentation and recognition of the saccharide chains of glycolipids at the cell surface: favoured conformations of the saccharide-lipid linkage calculated using molecular mechanics (MM3). , 1993, International journal of biological macromolecules.

[70]  J. Gariépy,et al.  Local conformational change in the B-subunit of Shiga-like toxin 1 at endosomal pH. , 1993, Biochemistry.

[71]  V. Jay,et al.  Experimental verocytotoxemia in rabbits , 1992, Infection and immunity.

[72]  Kristian Prydz,et al.  Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum , 1992, Nature.

[73]  S. Yiu,et al.  Glycolipid modification of alpha 2 interferon binding. Sequence similarity between the alpha 2 interferon receptor and verotoxin (Shiga-like toxin) B-subunit. , 1992, The Biochemical journal.

[74]  C. Lingwood,et al.  cells to Shiga toxin . sensitivity of human umbilical vein endothelial syndrome : effect of sodium butyrate on Shiga toxin-associated hemolytic uremic , 1991 .

[75]  M. Breimer,et al.  Glycosphingolipids of human large intestine: detailed structural characterization with special reference to blood group compounds and bacterial receptor structures. , 1991, Journal of biochemistry.

[76]  J. Brown,et al.  Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella dysenteriae 1 , 1989, The Journal of cell biology.

[77]  S. Saxena,et al.  Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. , 1989, The Journal of biological chemistry.

[78]  M. Breimer,et al.  Glycolipids of human large intestine: difference in glycolipid expression related to anatomical localization, epithelial/non-epithelial tissue and the ABO, Le and Se phenotypes of the donors. , 1988, Biochimie.

[79]  C. Lingwood,et al.  Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. , 1987, The Journal of biological chemistry.

[80]  C. Lingwood,et al.  Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice. , 1999, Oncology research.

[81]  C. Lingwood,et al.  Globotriaosyl ceramide (Gb3) expression in human tumour cells: intracellular trafficking defines a new retrograde transport pathway from the cell surface to the nucleus, which correlates with sensitivity to verotoxin. , 1998, Acta biochimica Polonica.

[82]  D. Brown,et al.  Functions of lipid rafts in biological membranes. , 1998, Annual review of cell and developmental biology.

[83]  J. Megyesi,et al.  Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. , 1997, Nephron.

[84]  B. Rosen,et al.  Expression of the verotoxin receptor glycolipid, globotriaosylceramide, in ovarian hyperplasias. , 1997, Oncology research.

[85]  C. Lingwood,et al.  Modelling of the interaction of verotoxin-1 (VT1) with its glycolipid receptor, globotriaosylceramide (Gb3). , 1995, International journal of biological macromolecules.

[86]  C. Lingwood.  Verotoxin-binding in human renal sections. , 1994, Nephron.